Diabetes
Conference Coverage
DURATION-8: Exenatide/dapagliflozin efficacy holds up at 1 year
SAN DIEGO – Uncontrolled type 2 diabetes may have met its match.
Conference Coverage
ODYSSEY: Alirocumab improves lipids but not glycemic targets in 2DM
New data: PCSK9 may lower LDL, but it has no effect on glucose control in the sickest patients with 2DM.
Conference Coverage
IDegLira equals basal-bolus insulin in HbA1c, lowers hypoglycemia risk
SAN DIEGO – When it comes to type 2 diabetes and insulin, “this is some of the most robust, most impressive data I’ve seen in years.”
Conference Coverage
Consistent weight benefits seen in empagliflozin use
Measures improved across age, gender, and degree of obesity.
From the Journals
Identifying type 1 diabetes drivers at risk of mishaps
When in comes to driving safely, past is prologue in diabetes.
Conference Coverage
CANVAS: Canagliflozin cuts cardiovascular events, doubles risk of amputations
SAN DIEGO – Would you accept this trade-off: Lower risk for MI, greater risk for amputation?
Conference Coverage
DEVOTE: Degludec and glargine had similar risk with less severe hypoglycemia
SAN DIEGO – Has glargine met its match?
Conference Coverage
Providers buck lipid recommendations in high-risk diabetes
SAN DIEGO – When the ADA issues diabetes care guidelines, does anyone listen?
Conference Coverage
Mild OSA linked to hypertension
Younger adults with nonsevere OSA were at increased risk of hypertension.
Conference Coverage
REMOVAL: Metformin may reduce cardiac risk in type 1 diabetes but doesn’t improve glucose control
SAN DIEGO – With disappointing results, metformin may not be as useful as previously thought.
Conference Coverage
Liraglutide produced cardiometabolic benefits in patients with schizophrenia
SAN DIEGO – Can the cardiometabolic risk factors associated with the use of some antipsychotic medications be prevented?